Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07434843 · ClinicalTrials.gov registry record · Phase 2
PH 2 Pemigatinib in SDH-deficient GIST
A Phase 2 study, sponsored by Dana-Farber Cancer Institute.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 24
- Enrollment target
NCT07434843 is a Phase 2 study that is actively recruiting participants, run by Dana-Farber Cancer Institute. The registered enrollment target is 24 participants.
The verdict
NCT07434843, a Phase 2 study, is actively recruiting participants, sponsored by Dana-Farber Cancer Institute.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 24 participants
- Enrollment target
Study Summary
The purpose of this study is to determine how effective the drug pemigatinib is as a treatment option for advanced succinate dehydrogenase (SDH)-deficient gastrointestinal stromal tumors(GIST). This study will also assess the side effects associated with pemigatinib and evaluate its tolerability. The name of the study drug involved in this study is: • Pemigatinib (INCB054828)
Interventions
- DRUG Pemigatinib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2026-05-19 |
| Est. Completion | 2029-04-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07434843
The ClinicalTrials.gov registry entry for NCT07434843 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 24 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Dana-Farber Cancer Institute, which has 781 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Pemigatinib is the first listed.
NCT07434843 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07434843 about?
NCT07434843 is a clinical study titled "PH 2 Pemigatinib in SDH-deficient GIST". The purpose of this study is to determine how effective the drug pemigatinib is as a treatment option for advanced succinate dehydrogenase (SDH)-deficient gastrointestinal stromal tumors(GIST). This study will also assess the side effects associated with pemigatinib and evaluate its tolerability. T...
What is the current status of trial NCT07434843?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 24 participants. The study started on 2026-05-19. Estimated completion is 2029-04-01.
What interventions are being tested in trial NCT07434843?
The interventions under investigation include: Pemigatinib (DRUG).
Who is sponsoring clinical trial NCT07434843?
This trial is sponsored by Dana-Farber Cancer Institute, which has 781 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.